A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism.
Saved in:
| Title: | A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism. |
|---|---|
| Authors: | Ing SW; Division of Endocrinology, Diabetes, and Metabolism Ohio State University Wexner Medical Center Columbus OH USA., Finkelman RD; Takeda Pharmaceuticals USA, Inc. Lexington MA USA., He P; Takeda Pharmaceuticals USA, Inc. Lexington MA USA., Khan AA; Divisions of Endocrinology and Metabolism and Geriatrics McMaster University Oakville ON Canada., Mannstadt M; Endocrine Unit Massachusetts General Hospital and Harvard Medical School Boston MA USA., Rejnmark L; Department of Clinical Medicine - Department of Endocrinology and Internal Medicine Aarhus University and Aarhus University Hospital Aarhus Denmark., Song I; Takeda Pharmaceuticals USA, Inc. Lexington MA USA., Takács I; Department of Internal Medicine and Oncology Semmelweis University Budapest Hungary., Wu Y; Takeda Pharmaceuticals USA, Inc. Lexington MA USA. |
| Source: | JBMR plus [JBMR Plus] 2023 May 31; Vol. 7 (7), pp. e10758. Date of Electronic Publication: 2023 May 31 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101707013 Publication Model: eCollection Cited Medium: Internet ISSN: 2473-4039 (Electronic) Linking ISSN: 24734039 NLM ISO Abbreviation: JBMR Plus Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2473-4039 |
|---|---|
| DOI: | 10.1002/jbm4.10758 |
